Sanofi Stock

Equities

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris 11:35:19 2024-04-16 am EDT 5-day change 1st Jan Change
86.79 EUR -0.75% Intraday chart for Sanofi -0.49% -3.31%
Sales 2024 * 46.12B 49.04B Sales 2025 * 49.74B 52.89B Capitalization 109B 116B
Net income 2024 * 7.38B 7.85B Net income 2025 * 8.79B 9.34B EV / Sales 2024 * 2.51 x
Net Debt 2024 * 6.86B 7.29B Net Debt 2025 * 2.8B 2.98B EV / Sales 2025 * 2.25 x
P/E ratio 2024 *
14.8 x
P/E ratio 2025 *
12.6 x
Employees 86,088
Yield 2024 *
4.36%
Yield 2025 *
4.73%
Free-Float 87.57%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.45%
1 week-0.18%
Current month-4.29%
1 month-1.07%
3 months-8.56%
6 months-16.19%
Current year-3.01%
More quotes
1 week
86.13
Extreme 86.13
88.52
1 month
86.12
Extreme 86.12
92.04
Current year
84.93
Extreme 84.93
96.50
1 year
80.60
Extreme 80.6
105.18
3 years
76.45
Extreme 76.45
106.66
5 years
67.65
Extreme 67.65
106.66
10 years
62.50
Extreme 62.5
106.66
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 19-08-31
Chief Operating Officer 39 21-12-31
Chief Tech/Sci/R&D Officer 51 -
Members of the board TitleAgeSince
Director/Board Member 70 14-04-30
Director/Board Member 62 20-04-27
Director/Board Member 64 20-05-21
More insiders
Date Price Change Volume
24-04-15 87.45 +1.13% 1,260,931
24-04-12 86.47 -0.23% 1,201,094
24-04-11 86.67 -1.65% 1,148,830
24-04-10 88.12 +1.03% 1,079,808
24-04-09 87.22 +0.25% 1,189,024

Real-time Euronext Paris, April 16, 2024 at 07:57 am EDT

More quotes
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
87.45 EUR
Average target price
107.5 EUR
Spread / Average Target
+22.92%
Consensus